Dongguan Anhao Pharmaceutical Technology

Dongguan Anhao Pharmaceutical Technology is a China-based biotechnology company specializing in the development of innovative small molecule drugs, with a core focus on Proteolysis Targeting Chimera (PROTAC) technology. Founded in the Songshan Lake High-tech Zone, the company targets high-value unmet medical needs in oncology and metabolic disorders. Their research and development efforts are centered on creating highly selective protein degraders that can overcome resistance mechanisms associated with traditional inhibitors. Anhao Pharmaceutical maintains a robust pipeline of preclinical and early-stage clinical candidates, including degraders for Bruton tyrosine kinase and the androgen receptor. The company aims to transform the treatment landscape for cancer and autoimmune diseases through its advanced protein degradation platform.